


RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy

Graphical abstract



Authors

Tarek Magdy, Zhengxin Jiang, Mariam Jouni, ..., Bruce C. Carleton, Daniel Bernstein, Paul W. Burridge

Correspondence

danb@stanford.edu (D.B.), paul.burridge@northwestern.edu (P.W.B.)

In brief

Magdy et al. use a rs2229774 doxorubicin-induced cardiotoxicity patient-specific model to functionally validate the role of this SNP in *RARG* as predictive of patients experiencing toxicity. They go on to demonstrate that *RARG* agonists attenuate cardiotoxicity in human and mouse models.

Highlights

- A rs2229774 patient-specific model recapitulates the patients' cardiotoxicity phenotype
- Introduction of rs2229774 increased doxorubicin-induced cardiotoxicity susceptibility
- *RARG* agonists attenuate cardiotoxicity without affecting chemotherapy efficacy
- Pharmacogenetic screening for rs2229774 and *RARG* agonists is a clinical option

Article

RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy

Tarek Magdy,^{1,2,9} Zhengxin Jiang,^{1,2,9} Mariam Jouni,^{1,2} Hananeh Fonoudi,^{1,2} Davi Lyra-Leite,^{1,2} Gwanghyun Jung,³ Marisol Romero-Tejeda,^{1,2} Hui-Hsuan Kuo,^{1,2} K. Ashley Fetterman,^{1,2} Mennat Gharib,^{1,2} Brian T. Burmeister,^{1,2} Mingming Zhao,³ Yadav Sapkota,⁴ Colin J. Ross,^{5,6} Bruce C. Carleton,^{5,7,8} Daniel Bernstein,^{3,*} and Paul W. Burridge^{1,2,10,*}

¹Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

²Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

³Department of Pediatrics (Division of Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA

⁴Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

⁵British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada

⁶Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada

⁷Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, BC V6T 1Z2, Canada

⁸Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, BC V5Z 4H4, Canada

⁹These authors contributed equally

¹⁰Lead contact

*Correspondence: danb@stanford.edu (D.B.), paul.burridge@northwestern.edu (P.W.B.)

<https://doi.org/10.1016/j.stem.2021.08.006>

SUMMARY

Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but its use is limited by dose-dependent cardiotoxicity. A recent genome-wide association study identified a SNP (rs2229774) in retinoic acid receptor- γ (*RARG*) as statistically associated with increased risk of anthracycline-induced cardiotoxicity. Here, we show that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from patients with rs2229774 and who suffered doxorubicin-induced cardiotoxicity (DIC) are more sensitive to doxorubicin. We determine that the mechanism of this *RARG* variant effect is mediated via suppression of topoisomerase 2 β (*TOP2B*) expression and activation of the cardioprotective extracellular regulated kinase (ERK) pathway. We use patient-specific hiPSC-CMs as a drug discovery platform, determining that the *RARG* agonist CD1530 attenuates DIC, and we confirm this cardioprotective effect in an established *in vivo* mouse model of DIC. This study provides a rationale for clinical prechemotherapy genetic screening for rs2229774 and a foundation for the clinical use of *RARG* agonist treatment to protect cancer patients from DIC.

INTRODUCTION

Advances in pharmacogenomics have been driven by both candidate gene and genome-wide association studies (GWASs) and have resulted in the identification of numerous single-nucleotide polymorphisms (SNPs) statistically associated with drug efficacy and toxicity. There is great need to develop suitable tools to fully validate these variants, because studies can be underpowered and variants discovered can be in non-coding regions, not change the amino acid sequence, or be in genes whose connection to drug efficacy or toxicity is unknown. Human models are required to establish variant function, because prior non-human models have proven inapplicable to patients (Cheng et al., 2011). A major advantage of human models is that they can provide in-depth and relevant mechanistic insight into how a specific genetic variant alters drug efficacy or toxicity (Musunuru et al., 2018) while providing a useful platform for subsequent drug discovery and facilitating rapid translation to the clinic.

The anthracycline doxorubicin (Adriamycin) is a prime candidate for this type of pharmacogenomic analysis. Doxorubicin is used in nearly 60% of pediatric cancer treatments (Hudson et al., 2013; van Dalen et al., 2014) and 35% of breast cancer treatments, and it has made a substantial contribution to the improvement in the average 5-year cancer survival rate, which exceeds 80% today. However, the presence of dose-dependent cardiotoxicity was recognized almost immediately after the introduction of doxorubicin treatment began (Lefrak et al., 1973; Swain et al., 2003; Von Hoff et al., 1979). 7%–10% of all childhood cancer survivors will develop heart failure up to 30 years after diagnosis (Mulrooney et al., 2009; van der Pal et al., 2012), and the risk of congestive heart failure in adult survivors of childhood cancer is 12 times higher compared with their siblings (Oeffinger et al., 2006). Despite its cardiotoxicity, doxorubicin is still widely used because of the lack of suitable alternatives.

The high interindividual variability in predisposition to doxorubicin-induced cardiotoxicity (DIC) (Granger, 2006; Hasan et al.,

2004; Krischer et al., 1997) has prompted more than 40 candidate gene SNP association studies (Blanco et al., 2012; Wojnowski et al., 2005) and a small number of GWASs, including our recent study on 456 pediatric cancer patients treated with anthracyclines (73 cases and 383 controls). This study identified the correlation (odds ratio = 4.7, $p = 5.9 \times 10^{-8}$) of a non-synonymous coding variant rs2229774 (S427L, NC_000012.11: g.1253605545G > A) in *RARG*, encoding retinoic acid receptor- γ , with DIC in both the original and two replication cohorts (Aminkeng et al., 2015). Although *RARG* has been known to play a role in cardiac looping during early development (Iulianella and Lohnes, 2002), the role of *RARG* in the mature heart is currently unknown. Variant rs2229774 occurs in approximately 15.3% of the population (global minor allele frequency of ~ 0.08 , 1000 Genomes; Auton et al., 2015), is only 16 bp downstream of the sequence that encodes the ligand binding domain of *RARG* (Figure 1A), and is predicted to be damaging to *RARG* function (PROVEAN/SIFT score 0.047). Although GWAS data such as these represent a potential major advance in applying a pharmacogenomic approach to cardio-oncology (Magdy et al., 2016), the connection between these SNP associations and clinical cardiotoxicity is far from proven (Boyle et al., 2017).

Our prior work has demonstrated that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) accurately recapitulate patients' predilection to DIC (BurrIDGE et al., 2016). hiPSC-CMs from breast cancer patients who developed DIC recapitulate that increased risk *in vitro*, with decreased cell viability, metabolic function, contraction, sarcomeric structure, and calcium handling and increased reactive oxygen species (ROS) production when exposed to doxorubicin compared with hiPSC-CMs from patients who were treated with doxorubicin but did not experience cardiotoxicity.

Using this platform, we validate the GWAS-identified variant rs2229774 as directly causative in DIC, confirming that cells from patients harboring this variant are at higher risk of DIC. We discover that a small-molecule *RARG* agonist significantly attenuates cardiomyocyte doxorubicin sensitivity both *in vitro* and *in vivo*, reducing murine acute cardiotoxicity by almost 50%. Further analyses reveal that *RARG*-associated DIC risk is mediated via two established mechanisms of cardiotoxicity, direct repression of topoisomerase 2 β (*TOP2B*) and regulation of extracellular regulated kinase (ERK) phosphorylation-mediated cardioprotection, pathways known to lead to downstream modulation of mitochondrial integrity. We have thus used patient-derived hiPSC-CMs as a platform to confirm a GWAS-suspected variant, discover the mechanism underlying the effect of that SNP, and develop and test a cardioprotective strategy using *RARG* agonists suitable for further clinical studies. Prechemotherapy genetic screening for rs2229774 and/or *RARG* agonist treatments have the potential to protect cancer patients from DIC.

RESULTS

Our previous work identified the DIC-associated *RARG* variant rs2229774 in a Canadian pediatric patient cohort and validated it in both Dutch and U.S. patient populations (Aminkeng et al., 2015). We returned to the Canadian cohort and specifically recruited these well-phenotyped, doxorubicin-exposed patients

using the original inclusion criteria (Table S1). We recruited three patients with the heterozygous rs2229774 variant and cardiotoxicity (S427L-1, S427L-2, and S427L-3, collectively S427L) and three control patients without the variant and without cardiotoxicity (Control-1, Control-2, and Control-3, collectively Control) (Figure 1A; Table S2). We derived hiPSCs from peripheral blood of these individuals, and all cell lines passed standard tests for pluripotency and genomic stability (Peterson and Loring, 2014; Figures S1A–S1C). We then differentiated these patient-derived hiPSCs into cardiomyocytes using our established protocol (BurrIDGE et al., 2014), resulting in average cardiomyocyte purity > 90% (Figures S1D–S1F).

hiPSC-CMs with the rs2229774 variant recapitulate patients' increased risk of DIC

We first sought to determine whether hiPSC-CMs with the *RARG* variant could recapitulate patient-specific increased risk of DIC *in vitro*. A concentration-dependent increase in sarcomeric disarray is a well-established effect of doxorubicin, demonstrated in both neonatal rat ventricular cardiomyocytes (Minotti et al., 2004) and our previous work in hiPSC-CMs (BurrIDGE et al., 2016). As assessed by immunofluorescent imaging, we observed a consistent effect of sarcomeric disarray in S427L hiPSC-CMs, but not in control cells, treated with 0.5 μM doxorubicin for 24 h (Figure 1B). Along with cytoskeletal damage, the S427L hiPSC-CMs showed significantly reduced cell viability after a 72 h treatment with doxorubicin compared with the control cells at all concentrations tested ($p < 0.0001$), with half-maximal lethal doses (LD_{50}) of 0.63 and 2.622 μM for S427L and control cells, respectively (Figure 1C; Figure S2A). After 24 h of doxorubicin treatment, apoptosis analysis demonstrated a concentration-dependent increase in cells positive for caspase-3/7 activity, with EC_{50} of 1.228 μM for S427L cells and 2.078 μM for control cells (Figure 1D; Figure S2B), suggesting that S427L hiPSC-CMs were more susceptible to programmed cell death. Because oxidative stress is one of the major mechanisms underlying the cardiotoxic effects of doxorubicin, we assessed ROS production after 24 h of doxorubicin treatment. ROS levels were significantly ($p < 0.0002$) higher in S427L than in the control cells across the tested concentrations (Figure S2C). Another mechanism for doxorubicin cardiotoxicity is induction of DNA damage, so we next assessed the level of double-stranded DNA breaks by staining for phosphorylated H2A histone family member X (γH2AX). We observed a concentration-dependent increase in DNA damage (Figure 1E), and the level of DNA damage was significantly higher in S427L cells than in control cells at all doxorubicin concentrations tested (Figure 1F). Combined, these data confirm that hiPSC-CMs from patients with the rs2229774 SNP are more sensitive to DIC.

Loss of function of *RARG* leads to increased DIC in hiPSC-CMs

To validate the role of *RARG* in regulating DIC, we generated *RARG* knockout (KO) and overexpression (OE) hiPSC-CMs from an isogenic control hiPSC line using CRISPR-Cas9-mediated genome editing (Figure 2). Altered *RARG* expression in these lines was confirmed at the RNA level by real-time RT-PCR, at the protein level by western blot, and by immunofluorescent imaging (Figure 3A). At the basal level, both of these lines




Figure 1. Patient-specific hiPSC-CMs with the *RARG* variant recapitulate increased risk of doxorubicin-induced cardiotoxicity

Comparison of hiPSC-CMs from control patients and patients harboring the heterozygous (S427L) rs2229774 variant in *RARG* after 24 or 72 h of doxorubicin treatment. Derived from three Control and three S427L patient hiPSC lines.

(A) Upper: *RARG* composed of the ligand-independent activation function (AF-1) domain, DNA binding domain (DBD), and ligand binding domain (LBD) that sets up the ligand-dependent AF-2 domain to recruit coactivators. Arrow indicates relative location of the *RARG* SNP. Lower: Sanger sequencing of Control (CC, major allele) and S427L (CT, minor allele) hiPSC lines. The asterisk indicates the SNP locus.

(B) Representative images for sarcomeric organization in hiPSC-CMs after 24 h of treatment with doxorubicin at the indicated concentrations, as assessed by immunofluorescence staining for α -actinin (ACTN2) and cardiac troponin T (TNNT2).

(C) Effect of doxorubicin (72 h) on hiPSC-CM viability. Control, $n = 22$; S427L, $n = 47$.

(D) Effect of doxorubicin (24 h) on apoptosis measured by caspase-3 and caspase-7 activity in hiPSC-CMs. Control, $n = 32$; S427L, $n = 55$.

(E) Representative images for immunofluorescent staining of DNA damage marker γ H2AX in hiPSC-CMs after 24 h of treatment with doxorubicin at the indicated concentrations.

(F) Quantification of γ H2AX staining in hiPSC-CMs by flow cytometry. Control, $n = 7$; S427L, $n = 12$.

Data are represented as mean \pm SD (C and D) or SEM (F); n.s., not significant; non-parametric bootstrap test (C and D) or unpaired two-tailed Student's *t* test (F). Scale bars, 25 μ m.

were phenotypically indistinguishable from their isogenic control and differentiated normally into cardiomyocytes (Figure S1), indicating that *RARG* was not required for pluripotency or cardiac

differentiation *in vitro*. We observed a consistent sarcomeric disarray in *RARG*-KO cells treated with 0.5 μ M doxorubicin, whereas this effect was rarely seen in *RARG*-OE cells, even at




Figure 2. CRISPR-Cas9-mediated knockout (KO) and overexpression (OE) of *RARG* gene in isogenic hiPSCs

(A) Schematic of the CRISPR-Cas9-mediated strategy to knock out the *RARG* gene. Shown are the genomic loci of the three major *RARG* splice variants, an enlarged view of the first exon with an alternative start codon (highlighted in blue), PAM and gRNA targeting sequences (underlined), the cutting site of Cas9 (vertical line), and PCR primers for Sanger sequencing.

(B) Schematic of the CRISPR-Cas9-mediated strategy for the overexpression *RARG*. Shown are the genomic locus of the *PPP1R12C* gene, an enlarged view of the *AAVS1* locus in the first intron of *PPP1R12C*, PAM and gRNA targeting sequences (underlined), the cutting site of Cas9 (vertical line), and PCR primers for Sanger sequencing of the *RARG* cDNA plasmid (containing most prevalent *RARG* splice variant 1 cDNA).

(C) Table summarizing all targeted modifications in the isogenic hiPSC line. All targeted modifications were determined by Sanger sequencing. One knockout clone with confirmed indels causing frameshift near the alternative start codons of all major *RARG* splice variants and clones with the correct *RARG* cDNA insertion were maintained for subsequent analysis.

1 μ M doxorubicin compared with *RARG* wild-type (WT) cells (Figure 3B). Consistently, *RARG*-KO hiPSC-CMs showed significantly reduced cell viability ($p < 0.005$), whereas *RARG*-OE cells showed significantly improved viability ($p = 0.0064$) compared with *RARG*-WT cells at all doxorubicin concentrations tested, with LD₅₀ of 1.582, 2.724, and 2.061 μ M for *RARG*-KO, *RARG*-OE, and *RARG*-WT cells, respectively (Figure 3C). Analysis of apoptosis via caspase-3/7 activity demonstrated a doxo-

rubin concentration-dependent increase, with EC₅₀ of 0.314, 1.83, and 0.683 μ M for *RARG*-KO, *RARG*-OE, and *RARG*-WT cells, respectively (Figure 3D), suggesting that knockout of *RARG* increased doxorubicin-induced apoptosis, whereas overexpression attenuated it. Furthermore, we observed a doxorubicin concentration-dependent increase in ROS production (Figure S3A), mitochondrial membrane dysregulation (Figure S3B), and DNA damage (Figures 3E and 3F), and the levels of ROS,




Figure 3. Validation of *RARG* expression as correlated with doxorubicin-induced cardiotoxicity

(A) Expression of *RARG* in hiPSC-CMs with CRISPR-Cas9-mediated *RARG*-KO and AAVS1-based *RARG*-OE in an isogenic hiPSC line, detected by real-time PCR (top left), western blot (top right), and immunofluorescent staining (bottom).

(B) Representative images for sarcomeric organization in isogenic, *RARG* knockout, and *RARG* overexpression hiPSC-CMs after 24 h of treatment with doxorubicin at the indicated concentrations, as assessed by immunofluorescence staining for ACTN2 and TNNT2.

(C) Effect of doxorubicin (72 h) on hiPSC-CM cell viability. *RARG*-WT, $n = 27$; *RARG*-KO, $n = 13$; *RARG*-OE, $n = 17$.

(D) Effect of doxorubicin (24 h) on apoptosis measured by caspase-3 and caspase-7 activity in hiPSC-CMs. *RARG*-WT, $n = 15$; *RARG*-KO, $n = 18$; *RARG*-OE, $n = 32$.

(E) Representative images for immunofluorescent staining of DNA damage marker γ H2AX after treatment of hiPSC-CMs with the indicated concentrations of doxorubicin for 24 h.

(F) Quantification of γ H2AX staining in hiPSC-CMs by flow cytometry. *RARG*-WT, $n = 5$; *RARG*-KO, $n = 7$; *RARG*-OE, $n = 10$.

Data are represented as mean \pm SD (C and D) or SEM (A and F); n.s., not significant; non-parametric bootstrap test (C and D) or ANOVA (A and F). Scale bars, 25 μ m.

mitochondrial dysfunction, and DNA damage were significantly higher in *RARG*-KO hiPSC-CMs than in *RARG*-WT and *RARG*-OE hiPSC-CMs. Collectively, these data confirm that *RARG*

expression has an important role in influencing the level of DIC and suggest that loss of function of *RARG* underlies the effect of the rs2229774 SNP in DIC.

Doxorubicin treatment results in S427L-dependent transcriptome changes in patient-derived hiPSC-CMs

We next sought to investigate transcriptome changes of S427L and Control hiPSC-CMs in response to 1 μ M doxorubicin for 24 h using an unbiased approach. Principal-component analysis (PCA) of RNA sequencing (RNA-seq) data in all 37,557 genes revealed a clear distinction in hiPSC-CMs before and after doxorubicin treatment (Figure S4A). MA plot (Figure S4B) and heatmap (Figure 4A; Figure S4C) analysis shows the significant upregulation (adjusted $p < 0.05$) of genes associated with apoptosis, DNA damage, oxidative stress, and doxorubicin resistance and downregulation of genes associated with cardiac function resulting from doxorubicin treatment (Figures S4D and S4E; Table S3). Of particular note, S427L hiPSC-CMs had significantly higher baseline expression of *CAV3*, a gene that is required for doxorubicin-induced apoptosis, through activation of caspase-3 (Volonte et al., 2008). Pathway enrichment analysis revealed no significant difference between S427L and Control hiPSC-CMs at the basal level before doxorubicin treatment (Figure S4D). After treatment with doxorubicin, S427L hiPSC-CMs showed significantly more activation of doxorubicin-induced apoptosis, TP53 targets, and oxidative phosphorylation than did control cells. In contrast, doxorubicin resistance and DNA repair were more significantly activated in control cells than in S427L cells (Figure 4B; Figure S4E). This finding is consistent with our observation that S427L hiPSC-CMs exhibit greater sarcomeric disarray, apoptosis, ROS production, and DNA damage than control cells upon doxorubicin treatment. Furthermore, we observed significant upregulation of *RARG* in S427L hiPSC-CMs compared with control cells (Figures 4C and 4D), suggesting a compensatory mechanism for the loss of function of *RARG* in these cells.

We next sought to analyze how *RARG* variants might influence known mechanisms of DIC. In the mouse model, knockout of *Top2b* attenuates DIC (Zhang et al., 2012). We reanalyzed existing data and found that *RARG* binds a retinoic acid response element (RARE) 907 bp downstream of the *TOP2B* transcription start site (Delacroix et al., 2010; Lalevée et al., 2011). Genes crucial for mitochondrial biogenesis downstream of *TOP2B*, such as *PPARGC1A* and *PPARGC1B*, encoding the transcriptional coactivators PGC-1 α and PGC-1 β , were also significantly downregulated in S427L hiPSC-CMs compared with control cells (Figure 4C). The functional effect of these gene expression changes on mitochondrial membrane potential was validated using the lipophilic fluorochrome JC-10, in which the red/green fluorescence ratio was markedly reduced in S427L hiPSC-CMs, but not in control cells, at lower doxorubicin concentrations (Figure 4E).

As a second potential mechanism, we were interested in the existing well-established link between ERK activation and prevention of doxorubicin-induced cardiomyocyte damage (Fryer et al., 2001; Izumi et al., 2006; Šimončíková et al., 2008; Su et al., 2006; Xiang et al., 2009; Yang et al., 2016). In addition to the canonical RARE pathways, retinoic acids are known to function through a non-canonical pathway by directly binding protein kinase C α (PRCKA) (Ochoa et al., 2002), resulting in phosphorylation of extracellular regulated kinase (ERK1/2 or MAPK1/3) (Cañón et al., 2004), which leads to activation of the cyclic AMP (cAMP) response element binding (CREB) protein (Aggar-

wal et al., 2006), a transcription factor known to regulate many genes involved in cardiomyocyte survival (Ichiki, 2006). We observed significant increase in phosphorylated ERK (pERK) in S427L hiPSC-CMs upon doxorubicin treatment, compared with control cells (Figure 4F), suggesting that the effect of the *RARG* SNP on doxorubicin-activated ERK signaling may also play a role in DIC, a finding we investigate later.

Our data strongly suggest that *RARG* directly represses *TOP2B* expression and that the rs2229774 SNP disrupts this regulation, leading to increased *TOP2B*-mediated DNA damage and decreased mitochondrial biogenesis/function upon doxorubicin treatment and connecting *RARG* to a previously established mechanism of DIC (Zhang et al., 2012). *RARG* overexpression was as potent as *TOP2B* knockout for reducing DIC in hiPSC-CMs (Figure 5), suggesting that *RARG* agonism might be a suitable drug-based cardioprotective methodology to reduce *TOP2B*-related cardiotoxicity.

Introduction of the *RARG* variant rs2229774 increases hiPSC-CMs' sensitivity to DIC and confirms causality

To directly confirm that rs2229774 is the causative SNP for the increased risk of DIC, we used CRISPR-Cas9-mediated genome editing to introduce the CT rs2229774 variant allele into control patient-specific hiPSC lines that harbored the reference CC genotype (S427S). We generated four hiPSC lines that harbor the heterozygous genotype CT (S427L) (Figure 6A): two from Control-2 and two from Control-3. A common mistake made during the attempt to correct a heterozygous variant by homology-directed repair (HDR) is to obtain clones that look like they are homozygous for the major allele by Sanger sequencing of a small PCR amplicon around the target site and conclude that the correction was achieved. However, what happens quite commonly is that a large non-homologous end joining (NHEJ) insertion or deletion (indel) is induced on the minor allele chromosome, preventing PCR amplification of that allele and making a single hemizygous major allele site look like a homozygous major site. To avoid this, (1) we introduced the heterozygous allele (CC > CT) of rs2229774 into hiPSCs harboring the reference allele of that variant (CC), rather than correcting the heterozygous variant allele back to the homozygous reference allele, and (2) we introduced two additional synonymous variants, including a protospacer adjacent motif (PAM) blocking variant that once identified by Sanger sequencing of our PCR amplicons, confirms the amplification of both alleles (Figure 6A).

By comparing Control hiPSC-CMs with their edited cells (Control^{edited}), we found that the introduction of rs2229774 SNP significantly increased sensitivity to doxorubicin at all concentrations tested, as assessed by cell viability ($p < 0.0001$, Figure 6B), mitochondrial membrane potential (Figure 6C), and DNA damage (Figure 6D). These results confirm that the rs2229774 SNP alone is responsible for the increased risk of DIC.

RARG-specific agonists attenuate the cardiotoxicity of doxorubicin without impeding anticancer efficacy

Because our data indicated that loss of function of *RARG* caused by the rs2229774 SNP led to increased doxorubicin sensitivity, we next asked whether stimulating *RARG* signaling in S427L hiPSC-CMs could reduce doxorubicin sensitivity. We pre/co-treated cells with three *RARG*-specific small-molecule agonists




Figure 4. S427L-dependent transcriptome changes after doxorubicin treatment of patient-derived hiPSC-CMs

(A and B) Differential regulation of genes and pathways in Control and S427L hiPSC lines after treatment with 1 μ M doxorubicin for 24 h. Data were obtained using hiPSC-CMs from three patients per group, one cell line per patient (n = 3); 12 RNA-seq samples in total. (A) Heatmap of the top 100 most differentially expressed genes. (B) Pathway enrichment analysis of the most significant transcriptome changes, showing S427L-dependent differential response.

(C) Real-time PCR confirming the effect of the S427L SNP on the expression of *RARG* and selected genes involved in the *TOP2B* pathway after doxorubicin treatment of hiPSC-CMs. n = 3 per group. Expression was normalized to *ACTB*.

(D) Western blot showing S427L-dependent upregulation of *RARG* and *TOP2B*, both at the basal level and after doxorubicin treatment in hiPSC-CMs. n = 6. This figure is a composite; the original is provided in Figure S6A.

(E) Representative images of JC-10 staining for assessing mitochondrial membrane potential in patient-derived hiPSC-CM after treatment with doxorubicin at the indicated concentrations for 24 h. Scale bar, 100 μ m.

(F) Immunoassay analysis demonstrating significant upregulation of ERK phosphorylation in S427L hiPSC-CMs compared with Control. n = 4 per group.

Data are represented as mean \pm SEM; n.s., not significant; unpaired two-tailed Student's t test.

(BMS961, CD437, and CD1530) or the general retinoic acid receptor (RAR) agonist all-*trans* retinoic acid (ATRA) at concentrations of 0, 0.3, 1, and 10 μ M and assessed cell viability after doxorubicin treatment for 72 h over a 5-log concentration range.

All of these agonists were able to improve cell viability, with CD1530 being the most effective at an optimal concentration of 1 μ M, increasing LD₅₀ by 4- and 7-fold for Control and S427L hiPSC-CMs, respectively (Figure 7A; Figure S5; Table S4). These




Figure 5. *TOP2B* knockout or *RARG* overexpression in isogenic hiPSC-CMs protects against doxorubicin-induced cardiotoxicity

(A) Schematic of the CRISPR-Cas9-mediated strategy to knock out the *TOP2B* gene. Shown is the genomic locus of *TOP2B*, an enlarged view of the first exon with the start codon (highlighted in blue), PAM and gRNA targeting sequences (underlined), the cutting site of Cas9 (vertical line), and PCR primers for Sanger sequencing.

(B) Table summarizing all targeted modifications in the isogenic hiPSC line. Indels were determined by Sanger sequencing.

(C) Western blot showing knockout of *TOP2B* in the isogenic hiPSC line. Sequencing and western blot confirmed knockout clones were maintained for subsequent analysis.

(D) Effect of doxorubicin (72 h) on hiPSC-CM viability. *TOP2B*-WT, n = 26; *TOP2B*-KO, n = 26; *RARG*-OE, n = 17.

Data are represented as mean \pm SEM; non-parametric bootstrap test.

findings indicate that activation of *RARG* signaling could reduce doxorubicin cardiotoxicity in hiPSC-CMs both with and without the rs2229774 SNP. Furthermore, activation of *RARG* signaling by CD1530 in S427L hiPSC-CMs increased *RARG* expression, repressed *TOP2B* expression, and upregulated genes involved in mitochondrial biogenesis (Figures 5B and 5C; Figure S6A). To confirm the mechanism of action of CD1530, we tested whether CD1530 protects *TOP2B* knockout hiPSC-CMs against DIC. We found that CD1530 did not alter the DIC sensitivity in *TOP2B* knockout cardiomyocytes. This finding demonstrates that CD1530 exerts its cardioprotective action mainly on the *RARG*-mediated attenuation of *TOP2B* (Figure 7D).

To further investigate the non-canonical retinoic acid pathway, we assessed pERK in hiPSC-CMs treated with doxorubicin, with or without pre/cotreatment with CD1530, and we found a significant increase in pERK in CD1530-treated cells (Figure 7E). Furthermore, inhibition of ERK signaling using the MEK1/2 inhibitor U0126 (Yang et al., 2016) abolished the protective effect of CD1530 (Figure 7F), confirming *RARG* agonism allows the pERK-dependent cardioprotective mechanism to function.

To investigate whether *RARG* agonists could attenuate DIC *in vivo*, we treated mice with doxorubicin (3 mg/kg intraperitoneal twice weekly for 3 weeks) plus oral CD1530, ATRA, or vehicle control. Doxorubicin treatment results in a steady decline in car-

diac function, as assessed by fractional shortening. Critically, cardiac function was significantly higher at three weeks with CD1530 ($p < 0.05$) and was marginally improved with ATRA ($p = 0.05$), compared with vehicle treatment (Figures 7G and 7H). Furthermore, we observed significant upregulation of the pro-apoptosis protein inhibitor BCL2 and modest but non-significant downregulation of *TOP2B* in the murine hearts with treatment of CD1530, but not ATRA, whereas pERK was significantly increased with both CD1530 and ATRA treatment (Figure 7I). Lastly, to rule out the possibility that *RARG* agonists could diminish the effectiveness of doxorubicin against cancer cells, we studied four commonly used breast cancer cell lines and found that cotreatment with *RARG* agonists did not impede the anticancer efficacy of doxorubicin (Figure 7J; Figures S6B-S6D; Table S5).

DISCUSSION

We have demonstrated that hiPSC-CMs can recapitulate patient-specific differences in the predilection to DIC and can be used for the direct validation of GWAS-identified genetic variants. When coupled with CRISPR-Cas9-mediated genome editing, hiPSCs serve as a powerful new platform for pharmacogenomic evaluation of both drug efficacy and toxicity. This




Figure 6. Introduction of the *RARG* variant into Control hiPSCs increases sensitivity to doxorubicin-induced cardiotoxicity

(A) Generation of *RARG* rs2229774 edited clones (n = 4). rs2229774 SNP is marked by red asterisks. Additional introduced silent mutations are marked by green asterisks.

(B) Effect of doxorubicin (72 h) on hiPSC-CM viability. Control, n = 25; Control^{edited}, n = 40.

(C) Representative images of JC-10 staining for assessing mitochondrial membrane potential in hiPSC-CMs after treatment with doxorubicin at the indicated concentrations for 24 h. Scale bars, 100 μm.

(D) Representative images for immunofluorescent staining of DNA damage marker γH2AX in hiPSC-CMs after 24 h of treatment with doxorubicin at the indicated concentrations.

(E) Quantification of γH2AX staining in hiPSC-CMs by flow cytometry. Control, n = 4; Control^{edited}, n = 11–13.

Data are represented as mean ± SD (B) or SEM (D); n.s., not significant; non-parametric bootstrap test (B) or ANOVA (E).




Figure 7. An RARG-specific agonist protects against doxorubicin-induced cardiotoxicity

(A) Effect of RARG agonist CD1530 on the viability of S427L hiPSC-CMs after 72 h of doxorubicin treatment. n = 6 replicates for each data point.

(B) Western blot showing CD1530-dependent regulation of RARG and TOP2B.

(C) Effect of 1 μ M CD1530 on RARG expression and TOP2B signaling in the S427L hiPSC-CMs after 3 μ M doxorubicin treatment for 24 h, as assessed by real-time PCR, normalized to 18S. n = 3 replicates for each group.

(D) Assessment of cell viability of TOP2B knockout hiPSC-CMs after 72 h of doxorubicin and CD1530 cotreatment.

(E) Immunoblot analysis showing significant upregulation of ERK phosphorylation in Control hiPSC-CMs with CD1530 treatment in a dose-dependent manner. The fold change is the ratio of pERK between 1 and 0 μ M doxorubicin treatment for 24 h. n = 4 per group.

(F) Effect of CD1530 (1 μ M) and ERK inhibitor U0126 (30 μ M) on the viability of Control hiPSC-CMs after 72 h of doxorubicin treatment (10 μ M). n = 6 replicates for each data point.

(G) Representative M-mode echocardiograms of mice at baseline and three weeks after treatment with doxorubicin alone or in combination with CD1530 or ATRA. The scale is shown in centimeters.

(H) Changes in left ventricular fractional shortening (FS) at three weeks after treatment, normalized to the baseline.

(I) Relative expression of TOP2B, pERK, and BCL2 in the hearts of mice at three weeks after treatment as assessed by western blot and normalized to GAPDH.

(legend continued on next page)

platform can be extended to validating other GWAS-identified SNPs, both in the field of pharmacogenomics and potentially for any disease in which the phenotype can be modeled in the dish. By editing hiPSC lines derived from patients with a specific disease phenotype, we can query a single SNP as the sole experimental variable while maintaining other SNPs that may influence the phenotype.

The mechanisms by which doxorubicin affects cancer cells and causes cardiotoxicity are thought to be different, providing an opportunity for the development of cardioprotective agents that do not interfere with chemotherapeutic efficacy. Cancer cells rely on topoisomerase 2 α (TOP2A) to introduce double-stranded DNA breaks that release DNA torsional stress generated during rapid DNA replication. Doxorubicin inhibits the decoupling of TOP2A from DNA, preventing DNA religation and resulting in DNA damage (Yang et al., 2014). Doxorubicin also directly intercalates with DNA, causing interference with RNA transcription and DNA polymerases.

In the case of the toxicity of doxorubicin to cardiomyocytes, three major interrelated mechanisms have been proposed: (1) the production of ROS (Berlin and Haseltine, 1981) via redox cycling, using mitochondrial NAD(P)H oxidoreductases (Minotti et al., 2004) and complexing of doxorubicin with iron in mitochondria (Ichikawa et al., 2014), causing mitochondrial lipid peroxidation, mitochondrial permeability transition pore (MPTP) opening, and activation of programmed cell death (Singal and Iliakovic, 1998); (2) doxorubicin-TOP2B-DNA interaction, in which like TOP2A, TOP2B functions to release DNA torsional stress, although primarily during transcription (Zhang et al., 2012); and (3) calcium dysregulation, which results in the pumping of Ca²⁺ out of the sarcoplasmic reticulum, causing an increase in intracellular calcium levels and subsequent sarcomeric and myofibrillar disarray (Fajardo et al., 2011; Lim et al., 2004).

In our data, differences in the doxorubicin response of hiPSC-CMs carrying rs2229774 and Control hiPSC-CMs are evident in multiple processes that have been identified as downstream determinants of doxorubicin cardiotoxicity, including reduction in cell survival, sarcomeric integrity, ROS production, and mitochondrial function, along with increased apoptosis and DNA damage. We confirm that *RARG* directly represses TOP2B (Figure 4D), whereas the S427L variant leads to derepression of TOP2B, resulting in comparatively increased TOP2B-mediated DNA damage and decreased mitochondrial biogenesis/function upon doxorubicin treatment of hiPSC-CMs, a previously established mechanism of DIC (Zhang et al., 2012). Our work comparing the use of *RARG* overexpression with TOP2B knockout shows similar levels of DIC attenuation, although it is likely that both manipulations function via multiple downstream mechanisms, requiring substantial further research. Interestingly, retinoic acid receptors and topoisomerases are commonly colocalized within the genome, with TOP2B and *RARB* overlapping each other and TOP2A and *RARA* within 30 kb of each other. This genome topology is conserved as far back in evolu-

tion as *Xenopus*, suggesting that the control of topoisomerases by retinoic acid receptors may be an evolutionarily ancient mechanism.

Phosphorylation of ERK2 in response to doxorubicin is a well-established phenomenon in DIC that has been connected to mitochondrial protection (Yang et al., 2016). We confirm that this process is also present in hiPSC-CMs and that cells with rs2229774 do not as readily undergo this process. However, without further mechanistic understanding of the relationship between pERK and mitochondrial function and integrity, it is not currently possible to separate this variance from the other mechanisms simultaneously occurring.

Our demonstration that hiPSC-CMs can be used to validate the rs2229774 SNP as causative in DIC provides a powerful tool that can be used to screen other SNPs that have been associated with DIC, although most were discovered in smaller patient populations or using candidate gene-based methodologies rather than GWAS (Magdy et al., 2016). Ultimately, with suitably validated variants, it will be possible to use a genetic test to predict the risk of DIC in patients receiving anthracyclines.

Our data also provide strong support for prechemotherapy screening of all patients who will receive doxorubicin for the rs2229774 variant (Aminkeng et al., 2016). For patients who harbor this variant, increased cardiac monitoring, reduction of doxorubicin dosing, and/or the use of the only existing approved cardioprotectant, dexrazoxane, are recommended. In addition, *RARG* agonist treatment (such as CD1530) has the potential to further protect patients with or without the rs2229774 variant from cardiotoxicity.

LIMITATIONS OF THE STUDY

Although our functional validation of the rs2229774 and *RARG* in DIC are clear, the use of pharmacogenomic data clinically has been limited so far (Aminkeng et al., 2016, 2017). It is likely that revised guidelines from national-level organizations such as the American Society for Clinical Oncology (ASCO) and the American College of Cardiology (ACC) will be required to overcome this lack of uptake. Because currently not even a routine echocardiogram is required for doxorubicin-treated patients, this many prove unpalatable. The dramatic decline in the cost of genetic screening and analyses has increased the accessibility of patients to such tests. Thus, a wider clinical application of genetic screening will provide the data to increase confidence in the rs2229774 SNP-DIC statistical association. In regard to CD1530 (and CD437 and BMS961), these drugs are tool compounds and not approved to be used in routine clinical practice; therefore, development of an alternative or derivative compounds will be required. Further basic and clinical research on these alternatives or derivatives is clearly warranted, especially additional studies in multiple cancer types (such as patient-derived xenograph models) to prove that chemotherapy efficacy is not attenuated.

(J) Assessment of cell viability of the MCF7 breast cancer cell line after 72 h of doxorubicin and *RARG* agonist (1 μ M each) cotreatment. $n = 2$ replicates for each data point.

Data are represented as mean \pm SD (A, D, and J) or SEM (C, E, F, H, and I); n.s., not significant; non-parametric bootstrap test (A and J), unpaired two-tailed Student's *t* test (B), or ANOVA/non-parametric Kruskal-Wallis test (D, E, G, and H).

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Human induced pluripotent cell derivation
- **METHOD DETAILS**
 - Human induced pluripotent stem cell culture
 - Single nucleotide polymorphism karyotyping
 - CRISPR/Cas9 gRNA and donor vector design
 - CRISPR/Cas9-mediated genome editing of hiPSC
 - Cardiac differentiation
 - Immunofluorescent staining
 - Flow cytometry
 - Doxorubicin treatment
 - 384-well plate-based cell viability, caspase 3/7 activity, and reactive oxygen species (ROS) assays
 - Mitochondrial membrane potential assay
 - Flow cytometry-based DNA damage assay
 - RNA-seq gene expression analysis
 - Quantitative Real-time PCR
 - Western blot
 - Immunoassay analysis of phosphorylated ERK
 - Breast cancer cell lines
 - Mouse model of doxorubicin-induced cardiomyopathy and drug administration
 - Echocardiographic evaluation
 - Statistical methods

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.stem.2021.08.006>.

ACKNOWLEDGMENTS

This work was supported by NIH grants K99/R00 HL121177, R01 CA220002, and R01 CA261898; American Heart Association Transformational Project Award 18TPA34230105; and Leducq Foundation 19CVD02 (to P.W.B.); the Canadian Cancer Society (to C.J.R., B.C.C., and P.W.B.); Michael Smith Foundation for Health Research Scholar Award (to C.J.R.); and NIH R33 HL123655 (to D.B. and B.C.C.). Patients from which hiPSCs were derived were recruited by the Canadian Pharmacogenomics Network for Drug Safety (by B.C.C. and C.J.R.), which has received grant funding from the Canadian Institutes for Health Research (CIHR), the CIHR Drug Safety and Effectiveness Network, Genome Canada, Genome British Columbia, and the British Columbia Provincial Health Services Authority.

AUTHOR CONTRIBUTIONS

P.W.B., Z.J., and T.M. designed the research. T.M., Z.J., M.J., H.F., D.L.-L., M.R.-T., H.-H.K., K.A.F., M.G., B.T.B., and P.W.B. completed experiments. T.M. completed the bioinformatics analysis. G.J., M.Z., and D.B. designed and performed the mouse experiments. Y.S. aided statistical analysis. C.J.R. and B.C.C. determined the AIC phenotype to be used for patient recruitment and provided patient samples. P.W.B. supervised the project. P.W.B., Z.J., and T.M. and wrote the manuscript with input from all other authors.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 26, 2021

Revised: August 3, 2021

Accepted: August 6, 2021

Published: September 8, 2021

REFERENCES

- Aggarwal, S., Kim, S.W., Cheon, K., Tabassam, F.H., Yoon, J.H., and Koo, J.S. (2006). Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. *Mol. Biol. Cell* 17, 566–575.
- Aminkeng, F., Bhavsar, A.P., Visscher, H., Rassekh, S.R., Li, Y., Lee, J.W., Brunham, L.R., Caron, H.N., van Dalen, E.C., Kremer, L.C., et al.; Canadian Pharmacogenomics Network for Drug Safety Consortium (2015). A coding variant in *RARG* confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. *Nat. Genet.* 47, 1079–1084.
- Aminkeng, F., Ross, C.J., Rassekh, S.R., Hwang, S., Rieder, M.J., Bhavsar, A.P., Smith, A., Sanatani, S., Gelmon, K.A., Bernstein, D., et al.; CPNDS Clinical Practice Recommendations Group (2016). Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. *Br. J. Clin. Pharmacol.* 82, 683–695.
- Aminkeng, F., Ross, C.J.D., Rassekh, S.R., Rieder, M.J., Bhavsar, A.P., Sanatani, S., Bernstein, D., Hayden, M.R., Amstutz, U., and Carleton, B.C. (2017). Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. *Br. J. Clin. Pharmacol.* 83, 1143–1145.
- Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., and Abecasis, G.R.; 1000 Genomes Project Consortium (2015). A global reference for human genetic variation. *Nature* 526, 68–74.
- Berlin, V., and Haseltine, W.A. (1981). Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. *J. Biol. Chem.* 256, 4747–4756.
- Blanco, J.G., Sun, C.L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D.L., Ginsberg, J.P., Hudson, M.M., et al. (2012). Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group. *J. Clin. Oncol.* 30, 1415–1421.
- Boyle, E.A., Li, Y.I., and Pritchard, J.K. (2017). An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* 169, 1177–1186.
- Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Dieckel, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined generation of human cardiomyocytes. *Nat. Methods* 11, 855–860.
- Burridge, P.W., Holmstrom, A., and Wu, J.C. (2015). Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. *Curr. Protoc. Hum. Genet.* 87, 21.3.1–21.3.15.
- Burridge, P.W., Li, Y.F., Matsa, E., Wu, H., Ong, S.G., Sharma, A., Holmström, A., Chang, A.C., Coronado, M.J., Ebert, A.D., et al. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. *Nat. Med.* 22, 547–556.
- Cañón, E., Cosgaya, J.M., Scsucova, S., and Aranda, A. (2004). Rapid effects of retinoic acid on CREB and ERK phosphorylation in neuronal cells. *Mol. Biol. Cell* 15, 5583–5592.
- Chen, G., Gulbranson, D.R., Hou, Z., Bolin, J.M., Ruotti, V., Probasco, M.D., Smuga-Otto, K., Howden, S.E., Diol, N.R., Propson, N.E., et al. (2011). Chemically defined conditions for human iPSC derivation and culture. *Nat. Methods* 8, 424–429.
- Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., and Huang, B. (2013).

Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* 155, 1479–1491.

Cheng, H., Kari, G., Dicker, A.P., Rodeck, U., Koch, W.J., and Force, T. (2011). A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. *Circ. Res.* 109, 1401–1409.

Chou, B.K., Gu, H., Gao, Y., Dowey, S.N., Wang, Y., Shi, J., Li, Y., Ye, Z., Cheng, T., and Cheng, L. (2015). A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach. *Stem Cells Transl. Med.* 4, 320–332.

Delacroix, L., Moutier, E., Altobelli, G., Legras, S., Poch, O., Choukallah, M.A., Bertin, I., Jost, B., and Davidson, I. (2010). Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. *Mol. Cell. Biol.* 30, 231–244.

Fajardo, G., Zhao, M., Berry, G., Wong, L.J., Mochly-Rosen, D., and Bernstein, D. (2011). β 2-adrenergic receptors mediate cardioprotection through cross-talk with mitochondrial cell death pathways. *J. Mol. Cell. Cardiol.* 51, 781–789.

Fryer, R.M., Pratt, P.F., Hsu, A.K., and Gross, G.J. (2001). Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. *J. Pharmacol. Exp. Ther.* 296, 642–649.

Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.* 85, 348–362.

Granger, C.B. (2006). Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? *Circulation* 114, 2432–2433.

Hasan, S., Dinh, K., Lombardo, F., and Kark, J. (2004). Doxorubicin cardiotoxicity in African Americans. *J. Natl. Med. Assoc.* 96, 196–199.

Hudson, M.M., Ness, K.K., Gurney, J.G., Mulrooney, D.A., Chemaitilly, W., Krull, K.R., Green, D.M., Armstrong, G.T., Nottage, K.A., Jones, K.E., et al. (2013). Clinical ascertainment of health outcomes among adults treated for childhood cancer. *JAMA* 309, 2371–2381.

Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S.V., Mutharasan, R.K., Naik, T.J., and Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J. Clin. Invest.* 124, 617–630.

Ichiki, T. (2006). Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both? *Arterioscler. Thromb. Vasc. Biol.* 26, 449–455.

Iulianella, A., and Lohnes, D. (2002). Chimeric analysis of retinoic acid receptor function during cardiac looping. *Dev. Biol.* 247, 62–75.

Izumi, M., Masaki, M., Hiramoto, Y., Sugiyama, S., Kuroda, T., Terai, K., Hori, M., Kawase, I., and Hirota, H. (2006). Cross-talk between bone morphogenetic protein 2 and leukemia inhibitory factor through ERK 1/2 and Smad1 in protection against doxorubicin-induced injury of cardiomyocytes. *J. Mol. Cell. Cardiol.* 40, 224–233.

Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M., Epstein, M.L., and Lipshultz, S.E. (1997). Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. *J. Clin. Oncol.* 15, 1544–1552.

Lalévée, S., Anno, Y.N., Chatagnon, A., Samarut, E., Poch, O., Laudet, V., Benoit, G., Lecompte, O., and Rochette-Egly, C. (2011). Genome-wide in silico identification of new conserved and functional retinoic acid receptor response elements (direct repeats separated by 5 bp). *J. Biol. Chem.* 286, 33322–33334.

Lefrak, E.A., Pittha, J., Rosenheim, S., and Gottlieb, J.A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer* 32, 302–314.

Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res.* 41, e108.

Lim, C.C., Zupping, C., Guo, X., Kuster, G.M., Helmes, M., Eppenberger, H.M., Suter, T.M., Liao, R., and Sawyer, D.B. (2004). Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. *J. Biol. Chem.* 279, 8290–8299.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.

Magdy, T., Burmeister, B.T., and Burrige, P.W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? *Pharmacol. Ther.* 168, 113–125.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in anti-tumor activity and cardiotoxicity. *Pharmacol. Rev.* 56, 185–229.

Mulrooney, D.A., Yeazel, M.W., Kawashima, T., Mertens, A.C., Mitby, P., Stovall, M., Donaldson, S.S., Green, D.M., Sklar, C.A., Robison, L.L., and Leisenring, W.M. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ* 339, b4606.

Musunuru, K., Bernstein, D., Cole, F.S., Khokha, M.K., Lee, F.S., Lin, S., McDonald, T.V., Moskowitz, I.P., Quertermous, T., Sankaran, V.G., et al. (2018). Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research. *Circ. Genom. Precis. Med.* 11, e002178.

Oceguera-Yanez, F., Kim, S.I., Matsumoto, T., Tan, G.W., Xiang, L., Hatani, T., Kondo, T., Ikeya, M., Yoshida, Y., Inoue, H., and Woltjen, K. (2016). Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives. *Methods* 101, 43–55.

Ochoa, W.F., Corbalán-García, S., Eritja, R., Rodríguez-Alfaro, J.A., Gómez-Fernández, J.C., Fita, I., and Verdaguer, N. (2002). Additional binding sites for anionic phospholipids and calcium ions in the crystal structures of complexes of the C2 domain of protein kinase calpha. *J. Mol. Biol.* 320, 277–291.

Oeffinger, K.C., Mertens, A.C., Sklar, C.A., Kawashima, T., Hudson, M.M., Meadows, A.T., Friedman, D.L., Marina, N., Hobbie, W., Kadan-Lottick, N.S., et al.; Childhood Cancer Survivor Study (2006). Chronic health conditions in adult survivors of childhood cancer. *N. Engl. J. Med.* 355, 1572–1582.

Peterson, S.E., and Loring, J.F. (2014). Genomic instability in pluripotent stem cells: implications for clinical applications. *J. Biol. Chem.* 289, 4578–4584.

Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308.

Schmittgen, T.D., and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 3, 1101–1108.

Šimončíková, P., Ravingerová, T., and Barančík, M. (2008). The effect of chronic doxorubicin treatment on mitogen-activated protein kinases and heat stress proteins in rat hearts. *Physiol. Res.* 57 (Suppl 2), S97–S102.

Singal, P.K., and Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. *N. Engl. J. Med.* 339, 900–905.

Su, H.F., Samsamshariat, A., Fu, J., Shan, Y.X., Chen, Y.H., Piomelli, D., and Wang, P.H. (2006). Oleyethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure. *Endocrinology* 147, 827–834.

Swain, S.M., Whaley, F.S., and Ewer, M.S. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer* 97, 2869–2879.

van Dalen, E.C., Raphaël, M.F., Caron, H.N., and Kremer, L.C. (2014). Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. *Cochrane Database Syst. Rev.* 9, CD006647.

van der Pal, H.J., van Dalen, E.C., van Delden, E., van Dijk, I.W., Kok, W.E., Geskus, R.B., Sieswerda, E., Oldenburger, F., Koning, C.C., van Leeuwen, F.E., et al. (2012). High risk of symptomatic cardiac events in childhood cancer survivors. *J. Clin. Oncol.* 30, 1429–1437.

Volonte, D., McTiernan, C.F., Drab, M., Kasper, M., and Galbiati, F. (2008). Caveolin-1 and caveolin-3 form heterooligomeric complexes in atrial cardiac myocytes that are required for doxorubicin-induced apoptosis. *Am. J. Physiol. Heart Circ. Physiol.* 294, H392–H401.

Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Jr., Von Hoff, A.L., Rozenzweig, M., and Muggia, F.M. (1979). Risk factors for doxorubicin-induced congestive heart failure. *Ann. Intern. Med.* 91, 710–717.

- Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M.R., Suk, E.K., et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation* *112*, 3754–3762.
- Xiang, P., Deng, H.Y., Li, K., Huang, G.Y., Chen, Y., Tu, L., Ng, P.C., Pong, N.H., Zhao, H., Zhang, L., and Sung, R.Y. (2009). Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. *Cancer Chemother. Pharmacol.* *63*, 343–349.
- Yang, F., Teves, S.S., Kemp, C.J., and Henikoff, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. *Biochim. Biophys. Acta* *1845*, 84–89.
- Yang, L., Luo, C., Chen, C., Wang, X., Shi, W., and Liu, J. (2016). All-*trans* retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway. *Br. J. Pharmacol.* *173*, 357–371.
- Zhang, S., Liu, X., Bawa-Khalife, T., Lu, L.S., Lyu, Y.L., Liu, L.F., and Yeh, E.T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat. Med.* *18*, 1639–1642.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit polyclonal IgG anti-POU5F1	Invitrogen	A24867; RRID: AB_2650999
Mouse monoclonal IgG ₃ anti-SSEA4	Invitrogen	A24866; RRID: AB_2651001
Rat monoclonal IgG _{2a} anti-SOX2	Invitrogen	A24759; RRID: AB_2651000
Mouse monoclonal IgM anti-TRA-1-60	Invitrogen	A24868; RRID: AB_2651002
Mouse monoclonal IgG ₁ anti-ACTN2 (clone EA-53)	Sigma	A7811; RRID: AB_476766
Rabbit polyclonal IgG anti-TNNT2	Abcam	ab45932; RRID: AB_956386
Rabbit monoclonal IgG anti-RARG (KO validated)	Abcam	ab187159; RRID: NA
Mouse monoclonal IgG ₁ anti- γ H2AX	Sigma	05-636; RRID: AB_309864
Goat anti-rabbit IgG Alexa Fluor 488	Invitrogen	A-11008; RRID: AB_143165
Goat anti-mouse IgG ₁ Alexa Fluor 594	Invitrogen	A-21125; RRID: AB_2535767
Goat anti-mouse IgG ₁ Alexa Fluor 488	Invitrogen	A-21121; RRID: AB_143165
Goat anti-rabbit IgG Alexa Fluor 594	Invitrogen	A-11021; RRID: NA
Mouse monoclonal IgG ₃ SSEA4-488 (clone MC813-70)	BD Biosciences	560308; RRID: AB_1645371
Mouse monoclonal IgG ₁ POU5F1-647 (clone 40/Oct-3)	BD Biosciences	560307; RRID: AB_1645319
Mouse monoclonal IgG ₁ TNNT2-647 (clone 13-11)	BD Biosciences	565744; RRID: AB_1645371
Mouse monoclonal IgG _{2b} MYH-PE (clone MF20)	BD Biosciences	564408; RRID: AB_2739341
Isotype control: mouse IgG ₃ -488	BD Biosciences	563636; RRID: NA
Isotype control: mouse IgG ₁ -647	BD Biosciences	565571; RRID: NA
Isotype control: mouse IgG _{2b} -PE	BD Biosciences	555743; RRID: NA
Mouse monoclonal IgG ₁ anti-TOP2B (clone40/Topo II)	BD Biosciences	611493; RRID: AB_398953
Rabbit polyclonal IgG anti-RARG	Abcam	Ab191368; RRID: NA
Mouse monoclonal IgG anti- β -Tubulin	Invitrogen	MA5-18308; RRID: NA
Mouse monoclonal IgG _{2b} anti-TOP2B	R&D Systems	MAB6348; RRID: AB_10889629
Rabbit polyclonal anti-phosphorylated ERK1/2	Cell Signaling Technologies	9102; RRID: AB_330244
Chemicals, peptides, and recombinant proteins		
Recombinant human IL3	Peprotech	200-03
Recombinant human SCF	Peprotech	300-07
Recombinant human IGF1	Peprotech	100-11
Recombinant human EPO	Calbiochem	329871
Dexamethasone	Sigma	D4902
Recombinant human insulin	GIBCO	A11382IJ
L-ascorbic acid 2-phosphate trisodium salt	Wako	321-44823
Recombinant human transferrin	In Vitria	777TRF029
Recombinant human FGF2	Peprotech	100-18B
Recombinant human TGF β 1	Peprotech	100-21
Y27632	LC Labs	Y-5301
Recombinant human albumin	Oryzogen	OsHSA
CHIR99021	LC Labs	C-6556
Wnt-C59	Biorbyt	orb1881132
L-lactic acid	Sigma	199257
Doxorubicin hydrochloride	MedChem Express	HY-15142
CD1530	Tocris Bioscience	2554
BMS 961	Tocris Bioscience	3410
CD 437	Tocris Bioscience	1549

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Retinoic acid	Sigma	R2625
Staurosporine	MedChemExpress	HY-15141
Menadione	MedChemExpress	HY-B0332
FCCP	MedChemExpress	HY-100410

Critical commercial assays

MycAlert PLUS Kit	Lonza	LT07-705
Infinium CytoSNP-12 BeadChip Array	Illumina	WG-320-2101
CellTiter-Glo 2.0	Promega	G9242
Caspase 3/7-Glo	Promega	G8091
ROS-Glo H ₂ O ₂	Promega	G8820
JC-10	Enzo Life Sciences	ENZ-52305
TruSeq RNA Library Prep Kit v2	Illumina	RS-122-2001

Deposited data

Raw and analyzed data	This paper	GEO: GSE164637
-----------------------	------------	----------------

Experimental models: Cell lines

Control-1	This paper	Jiang et al.
Control-2	This paper	Jiang et al.
Control-3	This paper	Jiang et al.
S427L-1	This paper	Jiang et al.
S427L-2	This paper	Jiang et al.
S427L-3	This paper	Jiang et al.
19-3 <i>RARG</i> -OE	This paper	Jiang et al.
19-3 <i>RARG</i> -KO	This paper	Jiang et al.
Control-1 ^{edited-1}	This paper	Jiang et al.
Control-1 ^{edited-2}	This paper	Jiang et al.
Control-3 ^{edited-1}	This paper	Jiang et al.
Control-3 ^{edited-2}	This paper	Jiang et al.
MCF7 (invasive ductal carcinoma)	ATCC	HTB-22; RRID: CVCL_0031
Hs 578T (invasive ductal carcinoma)	ATCC	HTB-126; RRID: CVCL_0332
MDA-MB-231 (breast adenocarcinoma)	ATCC	HTB-26; RRID: CVCL_0062
MDA-MB-468 (breast adenocarcinoma)	ATCC	HTB-131; RRID: CVCL_0418

Experimental models: Organisms/strains

C57BL/6J mice	The Jackson Laboratory	000664
---------------	------------------------	--------

Oligonucleotides

18S (Hs99999901_s1)	Applied Biosystems	4331182
<i>ACTB</i> (Hs01060665_g1)	Applied Biosystems	4331182
<i>GAPDH</i> (Hs02786624_g1)	Applied Biosystems	4331182
<i>NANOG</i> (Hs02387400_g1)	Applied Biosystems	4331182
<i>POU5F1</i> (Hs00999632_g1)	Applied Biosystems	4331182
<i>SOX2</i> (Hs01053049_s1)	Applied Biosystems	4331182
<i>KLF4</i> (Hs00358836_m1)	Applied Biosystems	4331182
<i>LIN28</i> (Hs00702808_s1)	Applied Biosystems	4331182
<i>MYC</i> (Hs00153408_m1)	Applied Biosystems	4331182
<i>UTF1</i> (Hs00747497_g1)	Applied Biosystems	4331182
<i>DNMT3B</i> (Hs01003405_m1)	Applied Biosystems	4331182
<i>TERT</i> (Hs99999022_m1)	Applied Biosystems	4331182
ZFP42 (Hs00399279_m1)	Applied Biosystems	4331182
TP53 (Hs99999147_m1)	Applied Biosystems	4331182
<i>RARG</i> (Hs01559234_m1)	Applied Biosystems	4331182

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<i>TOP2B</i> (Hs00172259_m1)	Applied Biosystems	4331182
<i>PPARGC1A</i> (Hs00173304)	Applied Biosystems	4331182
<i>PPARGC1B</i> (Hs00993805_m1)	Applied Biosystems	4331182
Recombinant DNA		
pSpCas9(BB)-2A-GFP (PX458)	Addgene	48138
pSpCas9(BB)-2A-Puro (PX459) V2.0	Addgene	62987
pXAT2 (AAVS1 sgRNA expression vector)	Addgene	80494
pAAVS1-Nst-CAG-DEST (gateway cloning vector)	Addgene	80489
CCSB-Broad LentiORF - <i>RARG</i> Clon	Dharmacon	ccsbBroad304_01377
Software and algorithms		
Subread	Liao et al., 2013	http://subread.sourceforge.net/
FeatureCounts	Liao et al., 2013	http://subread.sourceforge.net/
DESeq2	Love et al., 2014	https://bioconductor.org/packages/release/bioc/html/DESeq2.html

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul Burrige (paul.burridge@northwestern.edu).

Materials availability

hiPSC lines used in this study are available from the lead contact lead contact, Paul Burrige (paul.burridge@northwestern.edu), with a completed Materials Transfer Agreement.

Data and code availability

RNA-seq data produced in this study is available on GEO with the accession number GEO: GSE164637. The software and algorithms for data analyses used in this study are published and referenced. Further details on data analysis and code customization are available from the lead contact, Paul Burrige (paul.burridge@northwestern.edu), upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human induced pluripotent cell derivation

All pluripotent and reprogramming cells were maintained at 37°C in Heracell VIOS 160i humidified incubators (Thermo Scientific) with 5% CO₂ and 5% O₂. During differentiation cells were maintained at 5% CO₂ and atmospheric O₂. Protocols were approved by the Northwestern University and University of British Columbia Institutional Review Boards. Patients had previously been genotyped with Illumina Infinium HumanOmniExpress array (738,432 SNPs). With informed written consent, ~9 mL of peripheral blood was taken from each volunteer and shipped at 4°C, samples were transferred to LeucoSep tubes (Greiner) filled with Histopaque-1077 (Sigma). 1 × 10⁶ isolated peripheral blood mononuclear cells (PMBC) were grown in 24-well tissue culture-treated plates (Greiner) in 2 mL of SFEM II (Stem Cell Technologies) supplemented with 10 ng/mL IL3, 50 ng/mL SCF (KITLG), 40 ng/mL IGF1 (all Peprotech), 2 U/mL EPO, 1 μM dexamethasone (both Sigma) (Chou et al., 2015). 50% of the medium (1 mL) was changed every other day. After 12 days of growth, 6 × 10⁴ cells were transferred to a well of a 24-well plate in 500 μL of SFEM II with growth factors supplemented with CytoTune-iPS 2.0 Sendai Reprogramming Kit viral particles (Invitrogen) (Fusaki et al., 2009) diluted to 10% of the manufacturer's recommendations. Cells were treated with 3.5 μL, 3.5 μL, and 2.2 μL of hKOS (0.85 × 10⁸ CIU/mL), hMYC (0.85 × 10⁸ CIU/mL), and hKLF4 (0.82 × 10⁸ CIU/mL), respectively at MOI of 5:5:3 (KOS:MYC:KLF4). 100% of the medium was changed after 24 h by centrifugation (300 × *g*, 4 min) to 2 mL fresh SFEM II with growth factors, and cells were transferred to one well of a 6-well plate (Greiner) coated with 2 mL of 1:800 growth factor reduced Matrigel (Corning) diluted in DMEM (Corning). 50% of the medium (1 mL) was then changed gently every other day. On d8 after transduction, 100% of medium was changed to E8 medium. E8 medium was made in-house as previously described (Chen et al., 2011) with minor modifications and consisted of DMEM/F12 (10-092-CM, Corning), 20 μg/mL *E. coli*-derived recombinant human insulin (GIBCO), 64 μg/mL L-ascorbic acid 2-phosphate trisodium salt (Wako), 5 μg/mL *Oryza sativa*-derived recombinant human transferrin (Invitria/VWR), 14 ng/mL sodium selenite (Sigma), 100 ng/mL recombinant human FGF2 (154 amino acids, *E. coli*-derived, Peprotech), 2 ng/mL recombinant human TGFβ1 (112 amino acid, HEK293-derived, Peprotech), and 100 ng/mL heparin sodium salt (> 180 U/mg, Sigma). Medium was changed every day. At d17

individual colonies were picked in to a Matrigel-treated 12-well plate (one colony per well). Subsequently, cells were expanded in Matrigel-coated 6-well plates by passaging using 0.5 mM EDTA (GIBCO) in DPBS without Ca^{2+} or Mg^{2+} (Corning) for 6 min at RT. Specific hiPSC clones used for this study were summarized in [Table S2](#). The identities of all parental hiPSC lines were confirmed by Sanger sequencing of the rs2229774 SNP after PCR amplification of the genomic DNA with the SNP primer set ([Table S6](#)).

METHOD DETAILS

Human induced pluripotent stem cell culture

Cells were routinely maintained in E8 medium (made as above) on 1:800 diluted growth factor reduced Matrigel. E8 was supplemented with 10 μM Rho kinase inhibitor (Y27632) (LC Labs), hereby referred to as E8Y, for the first 24 h after passage. Cells were passaged at a ratio of $\sim 1:12$ to 1:15 every 4 days using 6 min of 0.5 mM EDTA in DPBS at RT, achieving 80% confluence. Cell lines were used between passages 20 and 80. All cultures (pluripotent and differentiation) were maintained with 2 mL medium per 9.6 cm^2 of surface area or equivalent. All cultures were routinely tested for mycoplasma using a MycoAlert PLUS Kit (Lonza) and a Varioskan LUX (Thermo Scientific) plate reader.

Single nucleotide polymorphism karyotyping

Genomic DNA was extracted from the cell pellets using a Quick-DNA Miniprep Plus kit (Zymo). SNP karyotyping was performed using a whole-genome Infinium CytoSNP-12 BeadChip Array (Illumina) covering 300,000 SNP using a NextSeq 500 (Illumina). Data was analyzed using BlueFuse Multi software (Illumina).

CRISPR/Cas9 gRNA and donor vector design

To generate *RARG* and *TOP2B* knockout gRNA expression vectors, two gRNAs targeting alternative start codons of three major *RARG* splicing variants and one gRNA targeting the start codon of *TOP2B* were designed using an online CRISPR design tool (<https://zlab.bio/guide-design-resources> <http://tools.genome-engineering.org>) with minimal predicted off-target effect ([Ran et al., 2013](#)). DNA oligos (IDT) encoding each gRNA with BbsI ligation overhangs were annealed and inserted into the BbsI restriction site of a pSpCas9(BB)-2A-GFP (PX458, Addgene 48138) plasmid ([Ran et al., 2013](#)). The constructed gRNA expression plasmids were confirmed by Sanger sequencing (Eurofins) with the LKO1_5_primer (5'-GACTATCATATGCTTACCG-3').

To generate *RARG* overexpression vector, an *AAVS1* gRNA expression vector ([Oceguera-Yanez et al., 2016](#)) (pXAT2, Addgene 80494) was used to target *AAVS1* locus in the first intron of the *PPP1R12C* gene ([Oceguera-Yanez et al., 2016](#)). Donor plasmid was generated by inserting *RARG* cDNA (CCSB-Broad LentiORF - *RARG* Clone, Dharmacon ccsbBroad304_01377) under the CAG promoter of a pAAVS1-Nst-CAG-DEST gateway cloning vector (Addgene 80489), which has a neomycin selection cassette in addition to homology arms for *AAVS1*. The constructed *RARG* donor plasmid was confirmed by Sanger sequencing with the P3 primer set ([Table S6](#)).

CRISPR/Cas9-mediated genome editing of hiPSC

hiPSC were cultured in E8 medium to $\sim 80\%$ confluence before electroporation. Cells were harvested using TrypLE Express (GIBCO) for 3 min at RT and resuspended in E8Y medium. To generate *RARG* and *TOP2B* knockout hiPSCs, 5×10^6 cells from the isogenic *RARG*-WT hiPSC line were electroporated with 1 μg of Cas9 expressing plasmid (pSpCas9(BB)-2A-GFP (PX458), modified as above, ([Figure S3](#)). Cells were plated in to one Matrigel-coated 6-well plate and maintained for 48 h in E8Y medium followed by dissociation with TrypLE and FACS sorting (FACSARIA SORP, BD Biosciences) for cells expressing GFP, and subsequently plated at a low density (500 cells per 9.6 cm^2 of surface area) in E8Y medium. Individual colonies were picked and expanded ~ 12 days after electroporation. Correctly targeted clones were identified by Sanger sequencing with primers outside of the targeting region ([Table S6](#)).

To generate *RARG* overexpression hiPSCs, 5×10^6 cells from the isogenic *RARG*-WT hiPSC line were electroporated with 3 μg *AAVS1* gRNA expression vector (pXAT2, Addgene) and 1 μg *RARG* donor plasmid ([Figure 2B](#)). Cells were plated in to one Matrigel-coated 6-well plate and maintained for 48 h in E8Y medium on Matrigel-coated plates followed by E8Y medium supplemented with 100 $\mu\text{g}/\text{mL}$ of geneticin (GIBCO) for one week of neomycin selection. Neomycin resistant colonies were subsequently picked and validated for *RARG* insertion at *AAVS1* locus by Sanger sequencing with the P3 primer set ([Table S6](#)).

For *RARG* SNP rs2229774 editing, 1×10^6 cells from patient-specific control hiPSC lines were electroporated with 5 μg Cas9 expressing plasmid (pSpCas9(BB)-2A-Puro (PX459) V2.0), 3 μg gBlock that expresses a FE-modified sgRNA with an A-U flip and extended stem that cuts two bp away from the rs2229774 locus ([Chen et al., 2013](#)), and 3 μl of 100 μM 80 bp symmetric ssODN repair template. Electroplated cells were plated into one 6-well plate in E8Y for 48 h, cells were then selected with 0.3 $\mu\text{g}/\text{ml}$ of puromycin for 48 h in E8Y medium. Surviving individual clones were picked and expanded. DNA was isolated, and rs2229774 locus was PCR amplified and Sanger sequenced. Confirmed edited clones were expanded in E8 medium on Matrigel-coated plates.

Cardiac differentiation

Differentiation into cardiomyocytes was performed as previously described ([Figure S1D](#); [Burrige et al., 2014, 2015](#)). All cell lines for each individual experiment were differentiated in parallel to further reduce experimental variability. Briefly, hiPSCs were split at a 1:15 ratio using 0.5 mM EDTA as above and grown in E8 medium for 4 days reaching $\sim 80\%$ confluence. At the start of differentiation (day 0), E8 medium was changed to CDM3 ([Burrige et al., 2014](#)), consisting of RPMI 1640 (Corning), 500 $\mu\text{g}/\text{ml}$ *Oryza sativa*-derived

recombinant human albumin (Oryzogen), and 213 $\mu\text{g/ml}$ L-ascorbic acid 2-phosphate (Wako). For the first 24 h, CDM3 medium was supplemented with 6 μM of glycogen synthase kinase 3- β inhibitor CHIR99021 (LC Labs). On day 1, medium was changed to CDM3 and on day 2 medium was changed to CDM3 supplemented with 2 μM of Wnt inhibitor Wnt-C59 (Biorbyt). Medium was then changed on day 4 and every other day for CDM3. Contracting cells were noted from day 7. On day 10, medium was changed to CDM3-L consisting of RPMI 1640 no glucose (Corning), CDM3 supplement, and with 4 mM L-lactic acid diluted in 1 M HEPES (both Sigma-Aldrich). On day 14, cardiomyocytes were dissociated using DPBS for 20 min at 37°C followed by 1:200 Liberase TH (Roche) in DPBS for 20 min at 37°C, centrifuged at 300 g for 5 min, filtered through a 100 μm cell strainer (Fisherbrand). Live cells were counted using a LUNA-FL Dual Fluorescence cell counter (Logos Biosystems) then plated onto Matrigel-treated Nunc Lab-Tek II 8-chamber slides (50,000 cells per well), No 1.5 coverslips (100,000 cells per coverslip) in 12-well plates, 24-well plates (1×10^6 cells per well), or 384-well white-sided μClear plates (25,000 cells per well) (all Greiner), in CDM3 medium supplemented with 40% FBS (Seradigm, VWR) for 48 h and changed back to CDM3 medium thereafter. Cardiomyocytes were used for analysis between day 20 and 30 days after differentiation.

Immunofluorescent staining

hiPSCs were dissociated with 0.5 mM EDTA and plated onto Matrigel-coated Nunc Lab-Tek II 8-chamber slides in E8 medium for three days (E8Y for the first 24 h). Cells were fixed, permeabilized, and stained for POU5F1, SSEA4, SOX2, TRA-1-60 with the PSC 4-Marker Immunocytochemistry Kit (Invitrogen) according to manufacturer's instructions. Cardiomyocytes were dissociated with Liberase TH (as above) and plated onto Matrigel-coated Nunc Lab-Tek II 8-chamber slides as previously described and allowed to adhere and spread for a week. Cells were fixed with 4% paraformaldehyde (Electron Microscopy Services) in DPBS for 15 min at RT, permeabilized with 1% saponin (Sigma) in DPBS for 15 min at RT, blocked with 3% bovine serum albumin (BSA, Sigma) in DPBS for 30 min at RT, and stained overnight in 3% BSA/1% saponin/DPBS at 4°C with 1:200 polyclonal rabbit IgG anti-TNNT2 (Abcam, ab45932), 1:500 monoclonal mouse IgG₁ anti-ACTN2 (Sigma, A7811), 1:200 monoclonal rabbit IgG RARG (Abcam, ab187159), or 1:200 monoclonal mouse IgG₁ γ H2AX (Sigma, 05-636). Cells were washed and then stained with secondary antibodies 1:1000 Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 594 goat anti-mouse IgG₁, or Alexa Fluor 488 goat anti-mouse IgG₁, Alexa Fluor 594 goat anti-rabbit IgG (all Invitrogen) in 3% BSA/1% saponin/DPBS for 1 hr. at RT in the dark. Cells were washed three times and mounted with ProLong Diamond Antifade Mountant with DAPI (Invitrogen). Slides were imaged with a Ti-E inverted fluorescent microscope (Nikon Instruments) and a Zyla sCMOS camera (Andor) using NIS-Elements 4.4 Advanced software.

Flow cytometry

hiPSCs were dissociated with TrypLE Express (GIBCO) for 3 min at RT and 1×10^6 cells were transferred to flow cytometry tubes (Fisherbrand). For staining of surface markers, cells were incubated in 1% FBS and 0.09% sodium azide (Sigma) in DPBS using 1:20 mouse IgG₃ SSEA4-488 (BD Biosciences, 560308) for 30 min at RT then washed. For intracellular staining, cells were fixed and permeabilized with -20°C methanol (Fisher Bioreagents) for 10 min, washed with DPBS, and stained using 1:20 mouse IgG₁ POU5F1-647 (BD Biosciences, 560307), and mouse IgG₁ NANOG-647 (BD Biosciences, 561300) for 30 min at RT then washed. Isotype controls mouse IgG₃-488 (BD Biosciences, 563636) and mouse IgG₁-647 (BD Biosciences, 565571) were used to establish gating. For staining of intracellular markers, cardiomyocytes were dissociated with Liberase TH (as above), fixed and permeabilized with -20°C methanol for 10 min, washed with DPBS, and stained using 1:500 mouse monoclonal IgG₁ TNNT2-647 (BD Biosciences, 565744) or 1:500 mouse monoclonal IgG_{2b} MYH-PE (BD Biosciences, 564408) for 30 min at RT and washed again with DPBS. Isotype controls mouse IgG₁-647 (BD Biosciences, 565571) and mouse IgG_{2b}-PE (BD Biosciences, 555743) were used to establish gating. Human dermal fibroblasts showed no positive staining under these conditions. All cells were analyzed using a CytoFLEX (Beckman Coulter) with CytExpert 2.0 software.

Doxorubicin treatment

Doxorubicin hydrochloride (MedChem Express) was resuspended to 10 mM in cell culture-grade water (Corning) and aliquots were stored at -20°C . Day 30 hiPSC-CMs were treated for 24 h or 72 h with doxorubicin (0.01-100 μM) diluted in RPMI 1640 medium (no phenol red, Corning) supplemented with 500 $\mu\text{g/ml}$ recombinant human serum albumin (Oryzogen). For RARG agonist treatment, day 30 hiPSC-CMs were treated with respective agonists (all from Tocris, resuspended in DMSO) for 24 h prior to doxorubicin administration and then a second dose was co-administered with doxorubicin as above.

384-well plate-based cell viability, caspase 3/7 activity, and reactive oxygen species (ROS) assays

To measure cell viability after 72 h of doxorubicin (0.01-100 μM) treatment, CellTiter-Glo 2.0 (Promega) was used per manufacturer's instructions. Luminescence was measured using a VarioSkan Lux Multi-Mode Reader (Thermo Scientific) with an integration time of 0.25 s. 10 μM staurosporine (MedChemExpress) was used as a positive control. After 24 h of doxorubicin (0.01-100 μM) treatment, apoptosis and ROS was measured using Caspase 3/7-Glo and ROS-Glo H₂O₂ (both Promega) respectively according to manufacturer's instructions with an integration time of 1 s. 10 μM staurosporine and 50 μM menadione (both MedChemExpress) was used as a positive control, respectively. Data were analyzed using Prism 7.0 software (GraphPad) using standard dose-response guidelines.

Mitochondrial membrane potential assay

hiPSC-CMs were cultured on Matrigel-coated Nunc Lab-Tek II 8-chamber slides, treated with doxorubicin for 24 h, washed and stained with JC-10 (Enzo Life Sciences) diluted to 2 μ M in RPMI 1640, for 30 min at 37°C, then mounted with ProLong Diamond Anti-fade Mountant with NucBlue live cell stain (Invitrogen). 50 μ M FCCP (MedChemExpress) was used as a positive control. Slides were imaged with a Ti-E inverted fluorescent microscope (Nikon Instruments) and a Zyla sCMOS camera (Andor) using NIS-Elements 4.4 Advanced software.

Flow cytometry-based DNA damage assay

After 24 h of doxorubicin treatment, hiPSC-CMs were dissociated with Liberase TH as described before, processed with BD Cytofix/Cytoperm fixation/permeabilization kit per manufacturer's instructions, and stained with 1:20 mouse IgG₁ γ H2AX-647 (BD Biosciences, 560447) at 4°C for 30 min in the dark and washed again with DPBS. Isotype control mouse IgG₁-647 (BD Biosciences, 565571) was used to establish gating. Cells were analyzed using a CytoFLEX (Beckman Coulter) with CytExpert 2.0 software and Prism 7.0 software (GraphPad).

RNA-seq gene expression analysis

Day 30 hiPSC-CMs from 6 patients (3 Control and 3 S427L) were treated with 1 μ M doxorubicin or vehicle for 24 h. We have previously determined that this is a physiologically relevant dose (Burridge et al., 2016). RNA was extracted using TRI Reagent and Direct-zol RNA microprep kit (both Zymo) including on-column DNase digestion to remove genomic DNA. Samples were quantified using an Agilent 2100 Bioanalyzer and passed QC. Library preparation was done using a TruSeq RNA v2 kit (Illumina) and sequencing with NextSeq 500 instrument (Illumina) by Northwestern's NuSeq core facility, generating ~40 million single-end 75 bp reads for each sample. Reads were mapped to the GRCh38 reference human genome using Subread software (Liao et al., 2013). Gene expression levels and exon usage were estimated using featureCounts function in the Subread software (Liao et al., 2013). Differential gene expression analysis was done using DESeq2 package (Love et al., 2014) and R (v3.3.3). Bioinformatics script and codes for the analysis are available upon request.

Quantitative Real-time PCR

RNA was isolated using TRI reagent (Zymo) and Direct-zol RNA microprep kit (Zymo) including on-column DNase digestion to remove genomic DNA. cDNA was produced from 1 μ g of total RNA using Maxima H Minus cDNA Synthesis Master Mix (Thermo Scientific). All PCR reactions were performed in triplicate in a 384-well plate format using TaqMan Fast Advanced Master Mix in a QuantStudio 5 Real-Time PCR System (both Applied Biosystems) with following TaqMan Gene Expression Assays (Applied Biosystems): 18S (Hs99999901_s1), *ACTB* (Hs01060665_g1), *GAPDH* (Hs02786624_g1), *NANOG* (Hs02387400_g1), *POU5F1* (Hs00999632_g1), *SOX2* (Hs01053049_s1), *KLF4* (Hs00358836_m1), *LIN28* (Hs00702808_s1), *MYC* (Hs00153408_m1), *UTF1* (Hs00747497_g1), *DNMT3B* (Hs01003405_m1), *TERT* (Hs99999022_m1), *ZFP42* (Hs00399279_m1), *TP53* (Hs99999147_m1), *RARG* (Hs01559234_m1), *TOP2B* (Hs00172259_m1), *PPARGC1A* (Hs00173304) and *PPARGC1B* (Hs00993805_m1). Relative quantification of gene expression was calculated using $2^{-\Delta\Delta Ct}$ method (Schmittgen and Livak, 2008), normalized to the reference 18S, *ACTB*, or *GAPDH* and untreated control samples as specified in the figure legends.

Western blot

We washed and harvested cells in cold PBS and collected them by centrifugation at 20,000 \times g for 10 min. at 4°C. Pellet was lysed in PBS containing 1% SDS and protease inhibitors (cOmplete, ROCHE) and sonicated (2 pulses of 12 s at 125 Watt) to shear DNA. We centrifuged the samples at 20,000 \times g for 15 min. at RT to precipitate and discard the insoluble material and the protein concentration in the supernatant was quantified using BCA assay (Thermo Scientific) following manufacturer's instructions. 30 μ g protein from each sample was subjected to SDS-PAGE in a 10% acrylamide gel for 90 min. at 150 V. and transferred to a PVDF membrane (Immobilon-P, Millipore) at 240 mA. for 90 min. Membranes were blocked in TBST containing 5% BSA for 1 hr. at RT and incubated at 4°C overnight with the following primary antibodies: 1:1000 monoclonal rabbit IgG anti-RARG (Abcam, Ab191368), 1:250 monoclonal mouse IgG₁ anti-TOP2B (BD Bioscience, 611493), 1:5000 monoclonal mouse IgG anti- β -Tubulin (Invitrogen, MA5-18308). The membrane was washed three times for 10 min with TBST and incubated with the appropriate secondary antibody: 1:5,000 HRP-goat anti-mouse IgG or HRP-goat anti-rabbit IgG (Life Technologies, 626520 and 656120) for 1 hr. at RT. After three additional washes with TBST, membranes were developed by chemiluminescence (SuperSignal West Pico, Thermo Scientific). Signals were captured using a CCD camera-based imager (Azure Biosystems) and quantified using ImageJ software. Mice heart tissues were harvested and homogenized using lysis buffer (80 mM NaCl, 0.05% Triton X, 1 mM EDTA, 20 mM HEPES, 0.5% sodium deoxycholate, 1 mM DTT, 20 mM β -glycerophosphate) with TissueLyser LT (QIAGEN) and centrifuged at 10,000 rpm for 15 min at 4°C. Proteins were quantified with Bradford (Bio-Rad) and separated by TrisGlycine SDS/PAGE (Bio-Rad). Transferred proteins on nitrocellulose membrane were probed against TOP2B (R&D Systems), phosphorylated ERK1/2 (Cell Signaling Technologies), BCL2 (Santa Cruz Biotechnology), and GAPDH (Advanced ImmunoChemical).

Immunoassay analysis of phosphorylated ERK

hiPSC-CMs were collected in lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, pH 8.0) supplemented with Phosphatase Inhibitor II (1:100, Sigma-Aldrich), Phosphatase Inhibitor Cocktail 3 (1:100, Sigma-Aldrich), 1 mM NaVO₄ and protease inhibitors

(cOmplete, ROCHE). We centrifuged the samples at 50,000 g for 15 min. at 4°C to precipitate and discard the insoluble material and the protein concentration in the supernatant was quantified using BCA assay (Thermo Scientific) following manufacturer's instructions. 2.5 µg protein/sample were analyzed using the MSD Phospho(Thr202/Tyr204; Thr185/Tyr187)/Total ERK1/2 Assay Whole Cell Lysate Kit (Meso Scale Discovery, K15100D-1), according to manufacturer's recommendations. The ratio of phosphorylated ERK was normalized to Total ERK1/2 signal and analyzed using Prism 7.0 software (GraphPad).

Breast cancer cell lines

Four human breast cancer cell lines were used, MCF7 (ATCC HTB-22) and Hs 578T (ATCC HTB-126) both cultured in RPMI 1640 (Corning) with 10% FBS (Opti-Gold, GenDEPOT), MDA-MB-231 (ATCC HTB-26) and MDA-MB-468 (ATCC HTB-131) both cultured in DMEM (Corning) with 10% FBS. All cells were cultured on uncoated tissue culture plates (Greiner) and passaged with TrypLE Express (GIBCO).

Mouse model of doxorubicin-induced cardiomyopathy and drug administration

C57BL/6J Mice were treated with doxorubicin (NovaPlus) alone as a control (n = 16), either co-treated with ATRA (all-trans retinoic acid, R2625 Sigma-Aldrich) or CD1530 (RARG-specific agonist, CAS107430-66-0, Tocris Bioscience) as experimental groups (n = 8 and n = 10, respectively). Mice were pretreated with CD1530 or ATRA (12 mg/kg each) for 3 days (day -3 ~day 0) and at day 0, mice were treated with doxorubicin (3 mg/kg) intraperitoneally twice a week and CD1530 or ATRA once a day by oral gavage for 3 weeks (day 0-day 21). For the control group, we treated mice with corn oil in the same schedule as agonist administration. We recorded an echocardiogram once a week (day 0, day 7, day 14, and day 21) and terminated the experiment at day 21. Hearts were harvested for western blot analyses as mentioned above.

Echocardiographic evaluation

Mice were studied at baseline and weekly during the protocol under light anesthesia with isoflurane (induction 3%, maintenance 1.5%). 2D images in the parasternal short axis were obtained with a GE Vivid 7 ultrasound system (GE Healthcare) equipped with a 13 MHz transducer. Left ventricular end-systolic (LVESD) and end-diastolic (LVEDD) dimensions were measured and left ventricular fractional shortening (FS) was calculated.

Statistical methods

Data were analyzed in Excel or R and graphed in GraphPad Prism 7. Detailed statistical information is included in the corresponding figure legends. Comparisons were conducted via one-way ANOVA test, an unpaired two-tailed Student's t test, or bootstrap testing with significant differences defined as $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****). Our sample size (3 patients in each category) was based on the feasibility of handling this number of hiPSC lines. Patient exclusion criteria are outlined in [Table S1](#). No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.